PYXS Relative Valuation
PYXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PYXS is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for PYXS's competitors is 148.09, providing a benchmark for relative valuation. Pyxis Oncology Inc Corp (PYXS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Pyxis Oncology Inc (PYXS) currently overvalued or undervalued?
What is Pyxis Oncology Inc (PYXS) fair value?
How does PYXS's valuation metrics compare to the industry average?
What is the current P/B ratio for Pyxis Oncology Inc (PYXS) as of Apr 28 2025?
What is the current FCF Yield for Pyxis Oncology Inc (PYXS) as of Apr 28 2025?
What is the current Forward P/E ratio for Pyxis Oncology Inc (PYXS) as of Apr 28 2025?